{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"An adverse event was any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. TEAEs were any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered.","groups":[{"description":"Participants with Ovarian Cancer (OC) received recommended phase 2 dose (RP2D) of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 2 OC: Niraparib 200 mg + Pembrolizumab"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) received RP2D of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 2 TNBC: Niraparib 200 mg + Pembrolizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set. Only those participants with data available at specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to a maximum of 54 months","title":"Phase 2: Number of Participants With TEAEs","type":"SECONDARY","unitOfMeasure":"Participants"}